Related Experiment Video

Updated: Jun 2, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer

Shou Wei Han1, Jesse Roman

  • 1Shou Wei Han, Jesse Roman, Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, United States.

World Journal of Biological Chemistry
|May 4, 2011
PubMed

Insights

Peroxisome proliferator-activated receptors gamma (PPARγ) ligands show promise in reducing lung cancer growth and metastasis. Emerging research suggests these ligands may offer a new therapeutic strategy for combating lung cancer.

Area of Science:

  • Molecular biology
  • Oncology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors.
  • PPARγ is a well-studied PPAR subtype with roles in metabolic diseases and cancer.
  • PPARγ is expressed in lung tumors and influences cancer progression.

Purpose of the Study:

  • To review current research on PPARγ ligands in lung cancer.
  • To explore the mechanisms of PPARγ ligands in anti-lung cancer strategies.
  • To evaluate the potential of PPARγ ligands as a novel lung cancer treatment.

Main Methods:

  • Review of preclinical studies in lung cancer models (gynogenic and xenograft).
  • Analysis of emerging retrospective clinical data.
  • Examination of molecular mechanisms underlying PPARγ function in lung cancer.

Main Results:

  • PPARγ ligand treatment decreased tumor growth and metastasis in preclinical models.
  • Retrospective clinical studies suggest a protective effect of PPARγ ligands against lung cancer incidence.
  • PPARγ's role is implicated in lung cancer development, progression, and metastasis.

Conclusions:

  • PPARγ ligands demonstrate therapeutic potential as an anti-lung cancer strategy.
  • Further research into PPARγ mechanisms could lead to novel treatments.
  • PPARγ ligands may represent a promising novel approach for lung cancer therapy.
Keywords:
Gene expression and regulationHuman lung cancerLigandsPeroxisome proliferator-activated receptor γSignaling pathwaysTherapy

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...